Daptomycin

• MRSA Infections
• Skin and Soft Tissue Infections
• Bacteremia (Bloodstream Infections)
• Infective Endocarditis

Daptomycin is a cyclic lipopeptide antibiotic used to treat serious infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). This bactericidal antibiotic has a unique mechanism of action that maintains activity against many drug-resistant organisms.

Mechanism of Action

Daptomycin has a distinctive mechanism that differs from other antibiotics. It binds to bacterial cell membranes in a calcium-dependent manner, inserting its lipophilic tail into the phospholipid bilayer. This insertion causes rapid depolarization of the membrane potential, leading to inhibition of protein, DNA, and RNA synthesis, and ultimately cell death without cell lysis. Because daptomycin does not penetrate the bacterial cell or target intracellular processes, it is less susceptible to resistance mechanisms affecting cell wall synthesis or ribosomal function. The calcium-dependent mechanism means that daptomycin is inactivated by pulmonary surfactant, making it ineffective for pneumonia.

Available Formulations

Daptomycin is available as a lyophilized powder for intravenous injection in 350 mg and 500 mg single-dose vials. The reconstituted solution is further diluted in 0.9% sodium chloride for infusion over 30 minutes (or as a 2-minute IV push for certain doses). Solutions should be used within 12 hours at room temperature or 48 hours if refrigerated. The medication is not available in oral form.

Medical Uses

Daptomycin is FDA-approved for complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria including MRSA, and for Staphylococcus aureus bloodstream infections (bacteremia) including right-sided infective endocarditis. It is NOT approved for pneumonia due to inactivation by surfactant. Off-label uses include bone and joint infections, left-sided endocarditis (in combination), and other serious MRSA infections. It is a valuable option when vancomycin cannot be used or has failed.

Dosing Guidelines

For complicated skin infections, the dose is 4 mg/kg IV once daily for 7-14 days. For S. aureus bacteremia and right-sided endocarditis, the dose is 6 mg/kg IV once daily for 2-6 weeks. Higher doses (8-10 mg/kg) are sometimes used off-label for serious infections. For patients with CrCl less than 30 mL/min (including hemodialysis and CAPD), the dose is 4-6 mg/kg every 48 hours, administered after hemodialysis on dialysis days. Dosing should be based on actual body weight.

Important Safety Information

Daptomycin can cause myopathy and rhabdomyolysis. Creatine phosphokinase (CPK) levels should be monitored weekly during treatment, and the medication should be discontinued if CPK levels rise significantly or if myopathy symptoms develop. Eosinophilic pneumonia has been reported; patients developing fever, dyspnea, and pulmonary infiltrates should be evaluated. Peripheral neuropathy has occurred. The medication should not be used for pneumonia due to inactivation by surfactant. Clostridioides difficile-associated diarrhea may occur.

Drug Interactions

HMG-CoA reductase inhibitors (statins) should be temporarily discontinued during daptomycin therapy due to additive myopathy risk. If statin therapy cannot be interrupted, CPK monitoring should be intensified. Warfarin anticoagulation may be affected; INR should be monitored closely. Tobramycin and other aminoglycosides may enhance nephrotoxicity if used concurrently. Daptomycin does not interact with cytochrome P450 enzymes.

Special Populations

Limited data exist on daptomycin use during pregnancy; use only if clearly needed. It is unknown whether daptomycin is excreted in human breast milk; caution is advised during breastfeeding. Safety and efficacy have been established in pediatric patients 1-17 years for skin infections and 1-17 years for S. aureus bacteremia. Elderly patients do not require dose adjustment based on age alone. Dose adjustment is required for renal impairment (CrCl less than 30 mL/min); no dosage adjustment is recommended for mild to moderate renal impairment. No dose adjustment is needed for hepatic impairment.